Personalized cell therapy is a form of disease-specific treatment that involves infusing living cells into a patient's body to treat conditions like cancer and autoimmune illnesses. It has many uses, including organ transplants, packed red blood cell transfusions, whole blood transfusions, and platelet transfusions. It is used to treat a variety of chronic disorders, including diabetes, cancer, spinal cord injuries, Parkinson's disease, and amyotrophic lateral sclerosis (both neurological diseases). Rising financial burden brought on by neurological illnesses is anticipated to drive the expansion of the global market for individualized cell therapy. The global customized cell treatment market is expanding as a result of the rising development of tailored cell therapy products and the increased prevalence of lifestyle illnesses.
During the forecast period (2019–2027), the global Personalized Cell Therapy Market is anticipated to have a CAGR of 23.5%.
Major Players in the Personalized Cell Therapy Industry:
1. Cytori Therapeutics Inc.
Cytori Therapeutics Inc. is a developer of autologous cell therapies, founded in 1996 and is headquartered in California, United States. It operates its business in China, Australia, Singapore, Malaysia and Hong Kong since 2013 and across the world.
2. Bellicum Pharmaceuticals, Inc.
Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is driving the future of cellular immune-oncology (IO). It was founded in 2004 and headquartered in United States. It operates in the US. Following an evaluation of the risk/benefit profile of BPX-601 in combination with rimiducid, Bellicum Pharmaceuticals, Inc. announced in March 2023 that it had decided to stop the ongoing Phase 1/2 clinical trials evaluating the safety and preliminary efficacy of GoCAR-T cell product candidates (including BPX-601 and BPX-603) in combination with rimiducid in patients who had received extensive prior chemotherapy.
3. Saneron CCEL Therapeutics, Inc.
Saneron CCEL Therapeutics, Inc. is a biotechnology R&D company, was founded in 1993 and headquartered in Florida, United States. It operates across the world.
4. Vericel Corporation
Vericel Corporation is a public, American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed and founded in 1989 and headquartered in Massachusetts, United States. It operates in Denmark also. Vericel announced plans for a brand-new, cutting-edge cell therapy manufacturing facility to support future growth in February 2022.
5. Novartis AG
Novartis AG is a Swiss multinational pharmaceutical corporation, founded in 1996 and is headquarters at Basel, Switzerland. Novartis AG has partners in about 140 countries. Novartis and Carisma Therapeutics sign an initial agreement for the production of HER 2-targeted CAR-M cell therapy in March 2022.
6. Gilead Sciences, Inc.
Gilead Sciences, Inc. is an American biopharmaceutical company, was founded in198s7 and headquartered in California. United States. It operates in more than 35 countries worldwide. Kite (a Gilead company) expanded its business in the CAR-T Cell market by launching new CAR-T Cell Therapy operations in Brazil, Saudi Arabia, and Singapore in August 2022. Kite plans to make CAR-T Cell Therapy available in all regions of the world where patients do not have access to a prospective treatment for advanced blood cancers.
7. Celgene Corporation
Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs, was founded in 1986 and headquartered in New Jersey, United States. It operates in more than 50 countries worldwide.
8. Bluebird Bio, Inc
Bluebird Bio, Inc is a biotechnology company that develops gene therapies for severe genetic disorders, was founded in 1992 and headquartered in Massachusetts, United States. It operates in over 130 countries. In April, 2023, Buebird Bio said it had sent its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lovo-cel for people with sickle cell disease (SCD) who are 12 years or older and have a history of vaso-occlusive events.
9. Aurora Biopharma Inc
Aurora Biopharma Inc is a developing first-in-class for resistant life-threatening solid tumor, was founded in 2012 and headquartered in Berlin, Germany. It operates globally.
10. MolMed S.p.A.,
MolMed S.p.A., is a biotechnology company founded in 1996 and headquartered in Milan. It operated in 15 countries. In July 2020, MolMed was acquired by AGC Biologic S.p.A.
*Definition: Personalized medicine (PM) or precision medicine in oncology is an emerging approach for tumor treatment and prevention that takes into account inter- and intra-tumor variability in genes, tumor (immune) environment, and lifestyle and morbidities of each person diagnosed with cancer.11
